Jennison Associates LLC Lowers Position in Merck & Co., Inc. $MRK

Jennison Associates LLC cut its stake in Merck & Co., Inc. (NYSE:MRK) by 56.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,728,958 shares of the company’s stock after selling 3,520,379 shares during the quarter. Jennison Associates LLC’s holdings in Merck & Co., Inc. were worth $350,671,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. D.A. Davidson & CO. raised its holdings in shares of Merck & Co., Inc. by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after purchasing an additional 24,576 shares during the last quarter. Pinnbrook Capital Management LP boosted its holdings in Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock worth $2,450,000 after purchasing an additional 11,355 shares during the last quarter. Cibc World Market Inc. boosted its holdings in Merck & Co., Inc. by 32.6% during the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares during the last quarter. Handelsbanken Fonder AB boosted its holdings in Merck & Co., Inc. by 13.9% during the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after purchasing an additional 224,752 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its position in Merck & Co., Inc. by 410.5% in the 4th quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock worth $74,255,000 after purchasing an additional 567,249 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. 0.17% of the stock is currently owned by company insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 melanoma success: Moderna and Merck said their individualized mRNA vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a large Phase 3 trial. The combination significantly extended recurrence-free survival and reduced the risk of melanoma spreading compared with Keytruda alone. This represents the first positive late-stage result for a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: New growth opportunity for Keytruda: The results could expand Merck’s oncology franchise by pairing Keytruda with a mutation-targeted vaccine. The companies believe thousands of high-risk melanoma patients could eventually benefit, pending regulatory approval targeted for 2027. Similar trials are underway in lung, pancreatic, breast and other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Strategic importance before patent expiry: A successful vaccine-Keytruda combination could help support Merck’s oncology pipeline as Keytruda’s patent protection is expected to expire later this decade. Unusually heavy call-option activity also indicated heightened bullish trading interest.
• Neutral Sentiment: Broader market support: Relief in bond markets helped lift rate-sensitive healthcare stocks generally, providing an additional supportive backdrop for Merck’s move. However, the company’s advance was primarily tied to the vaccine announcement.
• Negative Sentiment: Important uncertainties remain: The companies released topline results, while investors and analysts await complete trial data. The vaccine still requires regulatory approval, and the commercial opportunity, pricing and longer-term benefits are not yet established. Merck also faces substantial future pressure from Keytruda’s eventual loss of exclusivity.

Wall Street Analyst Weigh In

Several research firms have commented on MRK. Argus increased their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. boosted their target price on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Guggenheim increased their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Citigroup started coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Fifteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $135.50.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $152.21 on Thursday. The firm has a market cap of $375.53 billion, a price-to-earnings ratio of 121.77, a P/E/G ratio of 5.83 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50. The firm’s 50-day simple moving average is $126.86 and its two-hundred day simple moving average is $120.74.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the previous year, the company earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.